← All companies
CATALYST PHARMACEUTICALS, INC.
CPRX - CIK 0001369568
Market cap$3.84 B
Rank#1606
SEC filings1,337
CATALYST PHARMACEUTICALS, INC. trades as CPRX and has a market capitalization of $3.84 B, making it the #1606 largest US-listed company by market value. In its fiscal 2025 annual report the company posted revenue of $588.99M, up 19.8% from the prior year and net income of $214.33M. This page tracks CATALYST PHARMACEUTICALS, INC. through 1,337 SEC filings, with financial statements and metrics updated as new reports are filed.
Key metrics
Revenue (latest FY)$588.99MFY 2025
Net income (latest FY)$214.33MFY 2025
Operating cash flow (latest FY)$208.67MFY 2025
Total assets (latest FY)$1.10BFY 2025
Net margin36.4%latest FY
Financial performance
Net profit margin expanded from -6800.7% to 36.4% over the same period - every figure below comes from the company's audited annual filings.
Key statistics
- Market cap
- $3.84 B
- Share price (derived)market cap / shares outstanding
- $31.34
- P/E ratio (trailing FY)
- 17.9
- EPS (diluted)FY 2025
- $1.68
- Shares outstandingas of 2026-05-07
- 0.12B
- Total equityas of 2026-03-31
- $1.01B
- Return on equity
- 21.2%
- Cash & equivalentsas of 2026-03-31
- $755.86M
Latest filings
| Filing | Type | Filed |
|---|---|---|
| Proxy materials | DEFA14A | 2026-05-12 |
| Quarterly report | 10-Q | 2026-05-11 |
| Major company event | 8-K | 2026-05-11 |
| Proxy materials | DEFA14A | 2026-05-08 |
| Proxy materials | DEFA14A | 2026-05-07 |
| Proxy materials | DEFA14A | 2026-05-07 |
| Major company event | 8-K | 2026-05-07 |
| Annual report (amended) | 10-K/A | 2026-04-30 |
Recent press releases
- Catalyst Pharmaceuticals Reports First Quarter 2026 Financial Results2026-05-11
_Delivered Q1 2026 Total Revenues_ _of $149.4 Million_
- Catalyst Pharmaceuticals Announces Settlement of FIRDAPSE® (amifampridine) Patent Litigation with Hetero Labs Ltd.2026-05-07
_As Part of the Settlement, Hetero Labs Ltd. Receives a License to Market Generic FIRDAPSE Beginning in January 2035_
- Catalyst Pharmaceuticals Cancels First Quarter 2026 Conference Call and Webcast2026-05-07
Catalyst Pharmaceuticals, Inc. (Nasdaq: CPRX), is a biopharmaceutical company committed to improving the lives of patients with rare diseases. With a proven track record of bringing life-changing treatments to the market, we focus on in-licensing, commercializing, and developing innovative therapies. Guided by our deep commitment to patient care, we prioritize accessibility, ensuring patients receive the care they need through a comprehensive suite of support services designed to provide seamless access and ongoing assistance. Catalyst maintains a well-established U.S. presence, which remains the cornerstone of our commercial strategy, while continuously evaluating strategic opportunities to expand our global footprint. Catalyst, headquartered in Coral Gables, Fla., has been recognized by Forbes as one of America’s Most Successful Company in 2023, 2024, and 2025, and on the 2025 Deloitte Technology Fast 500™ list as one of North America’s Fastest-Growing Companies.
- Catalyst Pharmaceuticals to Report First Quarter 2026 Financial Results on May 11, 20262026-04-28
The webcast will be accessible under the Investors section on the Company's website at www.catalystpharma.com. A webcast replay will be available on Catalyst’s website for at least 30 days following the date of the event.
Similar companies
The largest companies sharing CATALYST PHARMACEUTICALS, INC.'s SEC industry classification (pharmaceutical preparations).
Frequently asked questions
What is CATALYST PHARMACEUTICALS, INC.'s market cap?
CATALYST PHARMACEUTICALS, INC. (CPRX) has a market capitalization of $3.84 B as of 2026-06-10, ranking #1606 among US-listed companies.
How much revenue does CATALYST PHARMACEUTICALS, INC. make?
CATALYST PHARMACEUTICALS, INC. reported revenue of $588.99M for fiscal year 2025, an increase of 19.8% year over year.
Is CATALYST PHARMACEUTICALS, INC. profitable?
Yes. CATALYST PHARMACEUTICALS, INC. reported net income of $214.33M in its latest fiscal year.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.